Add new members to the Baxalta Hemophilia product line
November 19, 2015
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];-- The FDA recently announced the approval of Baxalta's long-acting A-type hemophilia therapy Adynovate, which is another good news for Baxalta in the field of hematology research since its predecessor, Baxter. The treatment is a long-lasting upgrade to Baxalta's current best-selling drug, Advate, which is currently the world's best-selling factor XIII.
Previously, Baxalta had high hopes for Adynovate (BAX855), which believed that the product would help the company further consolidate its position in the hemophilia market and compete with the same products that Baijian launched last year. It is understood that patients who receive Adynovate treatment only need to inject twice a week to achieve the effect of promoting normal blood coagulation of the wound.
However, it is not easy for Baxalta to want to be a big man in the hemophilia market. In addition to their old rival Baijian, Bayer's BAY 81-8973 is currently awaiting FDA approval. In addition, Novo Nordisk has a similar product in clinical phase III research.
However, for Baxalta, another big benefit of Adynovate's approval is to help the company resist Shire's acquisition pressure. As we all know, after the split of Baxter, Shire proposed an offer to acquire Baxalta, and the price of the entire acquisition has reached more than 30 billion US dollars. However, Baxalta, which just started its own business, apparently did not want to be incorporated by other companies so quickly. Company CEO Ludwig Hantson repeatedly publicly rejected the acquisition. Even in order to break Shire's thoughts, Hantson also ambitiously proposed a product development plan, hoping that the company will launch 20 new products by 2020, bringing the company's annual sales to a total of 8.5 billion US dollars.
However, for Shire, which is striving to build a leading position in the rare disease field, perhaps Adynovate's approval will only make it more interested in Baxalta. (Bio Valley Bioon.com)
We are a professional Chinese supplier of Anti-Allergy Material; we supply various products of Anti-Allergy Material; and we can providing product images and basic parameters with eachAnti-Inflammatory Ingredients, Anti-Microbial Ingredients and Remove Acne Materials. Look forward to your cooperation!
Calendula Extract,Chamomile Extract,Aloe Vera Extract,Mint Extract,Feverfew Extract
Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobio.com